Sandi Shen^1,2, Shizhen Zhong¹, Hai Lu², Wenhua Huang^1*, Gaofang Xiao³

Show more
¹ Department of Anatomy, Academic College, Southern Medical University, Guangzhou, China.
² Headneck and Breast Surgery, Yuebei People Hospital, Shantou University, Shaoguan, China.
³ Department of Pathology, Yuebei People Hospital, Shantou University, Shaoguan, China.
Show less

Abstract: Objectives: The invasive breast cancer is divided into four clinical subtypes: Luminal A-like, Luminal B-like, HER-2 positive, and triple-negative according to the expression status of estrogen receptor (ER), progesterone receptor(PR), human epidermal growth factor receptor-2 (HER-2) and Ki-67. The prognosis and treatment strategy vary with subtypes. The current studies have reported the relation between lymphatic vessel invasion (LVI) and the expression status of ER, PR, HER-2, Ki-67 in invasive breast cancer, but the results were debatable. So the meta-analysis was conducted to confirm the relation between LVI and the four factors. Methods: Literature was searched by entering the terms: breast AND (neoplasm OR cancer OR carcinoma) AND (lymphovascular OR “lymph vessel” OR “lymphatic vessel” invasion OR carcinoma embolus) AND (ER OR estrogen receptor OR PR OR progesterone receptor OR HER-2 OR human epidermal growth factor receptor-2 OR Ki-67 OR clinicopathological) in Pubmed. The merged odds ratio (OR) and 95% confidence interval (CI) were estimated using fixed-effect model. Review Manager 5.2 was used to analysis the relation between LVI and the expression status of ER, PR, HER-2, Ki-67 in invasive breast cancer respectively. The fail-safe number was used to estimate publication bias. Results: The analysis included 5 studies, LVI positive rate was significant lower in ER positive, PR positive, HER-2 negative, low Ki-67 expression group statistically. The OR and 95% CI were 0.6(0.44 - 0.81), 0.64(0.43 - 0.95), 1.52(1.03 - 2.24), 5.29(1.53 - 18.35) respectively.Conclusions: LVI was significantly correlated with the expression status of ER, PR, HER-2 and Ki-67 in invasive breast cancer. Furthermore, LVI was consistent with poor prognostic expression status of the four factors.

Keywords: Lymphatic Vessel Invasion, Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor-2, Ki-67, Breast Cancer

Cite this paper: Shen, S. , Zhong, S. , Lu, H. , Huang, W. and Xiao, G. (2015) A Meta-Analysis of Lymphatic Vessel Invasion Correlated with Pathologic Factors in Invasive Breast Cancer. Journal of Cancer Therapy, 6, 315-321. doi: 10.4236/jct.2015.64034.

References

[1]   Siegel, R., Ma, J., Zou, Z. and Jemal, A. (2014) Cancer Statistics, 2014. CA: A Cancer Journal for Clinicians, 64, 9-29.
http://dx.doi.org/10.3322/caac.21208

[2]   Schoppmann, S.F., Bayer, G., Aumayr, K., Taucher, S., Geleff, S., Rudas, M., et al. (2004) Prognostic Value of Lymphangiogenesis and Lymphovascular Invasion in Invasive Breast Cancer. Annals of Surgery, 240, 306-312.
http://dx.doi.org/10.1097/01.sla.0000133355.48672.22

[3]   Vleugel, M.M., Bos, R., van der Groep, P., Greijer, A.E., Shvarts, A., Stel, H.V., et al. (2004) Lack of Lymphangiogenesis during Breast Carcinogenesis. Journal of Clinical Pathology, 57, 746-751.
http://dx.doi.org/10.1136/jcp.2003.014480

[4]   Goldhirsch, A., Glick, J.H., Gelber, R.D., Gelber, R.D., Thürlimann, B., Senn, H.J., et al. (2005) Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 16, 1569-1583.

[5]   Arnaout-Alkarain, A., Kahn, H.J., Narod, S.A., Sun, P.A. and Marks, A.N. (2007) Significance of Lymph Vessel Invasion Identified by the Endothelial Lymphatic Marker D2-40 in Node Negative Breast Cancer. Modern pathology, 20, 183-191.

[6]   Braun, M., Flucke, U., Debald, M., Walgenbach-Bruenagel, G., Walgenbach, K.-J., Holler, T., et al. (2008) Detection of Lymphovascular Invasion in Early Breast Cancer by D2-40 (Podoplanin): A Clinically Useful Predictor for Axillary Lymph Node Metastases. Breast Cancer Research and Treatment, 112, 503-511.
http://dx.doi.org/10.1007/s10549-007-9875-2

[7]   Gujam, F.J., Going, J.J., Mohammed, Z.M., Orange, C., Edwards, J. and McMillan, D.C. (2014) Immunohistochemical Detection Improves the Prognostic Value of Lymphatic and Blood Vessel Invasion in Primary Ductal Breast Cancer. BMC Cancer, 14, 676.
http://dx.doi.org/10.1186/1471-2407-14-676

[8]   Lee, J.A., Bae, J.W., Woo, S.U., Kim, H. and Kim, C.H. (2011) D2-40, Podoplanin, and CD31 as a Prognostic Predictor in Invasive Ductal Carcinomas of the Breast. Journal of Breast Cancer, 14, 104-111.
http://dx.doi.org/10.4048/jbc.2011.14.2.104

[9]   Tezuka, K., Onoda, N., Takashima, T., Takagaki, K., Ishikawa, T., Wakasa, T., et al. (2007) Prognostic Significance of Lymphovascular Invasion Diagnosed by Lymphatic Endothelium Immunostaining in Breast Cancer Patients. Oncology Reports, 17, 997-1003.
http://dx.doi.org/10.3892/or.17.5.997

[10]   Widodo, I., Ferronika, P., Harijadi, A., Triningsih, F.E. and Soeripto, U.T. (2013) Clinicopathological Significance of Lymphangiogenesis and Tumor Lymphovascular Invasion in Indonesian Breast Cancers. Asian Pacific Journal of Cancer Preventio: APJCP, 14, 997-1001.
http://dx.doi.org/10.7314/APJCP.2013.14.2.997

[11]   Viale, G., Regan, M.M., Maiorano, E., Mastropasqua, M.G., Dell’Orto, P., Rasmussen, B.B., et al. (2007) Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 25, 3846-3852.

[12]   Goldhirsch, A., Ingle, J.N., Gelber, R.D., Gelber, R.D., Thürlimann, B., Senn, H.J., et al. (2009) Thresholds for Therapies: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 20, 1319-1329.

[13]   Goldhirsch, A., Winer, E.P., Coates, A.S., Gelber, R.D., Thürlimann, B., Senn, H.J., et al. (2013) Personalizing the Treatment of Women with Early Breast Cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 24, 2206-2223.

[14]   Prat, A., Cheang, M.C., Martin, M., Parker, J.S., Carrasco, E., Caballero, R., et al. (2013) Prognostic Significance of Progesterone Receptor-Positive Tumor Cells within Immunohistochemically Defined Luminal A Breast Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, 203-209.
http://dx.doi.org/10.1200/JCO.2012.43.4134

[15]   Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A. and McGuire, W.L. (1987) Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/Neu Oncogene. Science, 235, 177-182.
http://dx.doi.org/10.1126/science.3798106

[16]   Gonzalez-Angulo, A.M., Litton, J.K., Broglio, K.R., et al. (2009) High Risk of Recurrence for Patients with Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2-Positive, Node-Negative Tumors 1 cm or Smaller. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27, 5700-5706.
http://dx.doi.org/10.1200/JCO.2009.23.2025

[17]   Luporsi, E., Andre, F., Spyratos, F., Martin, P.-M., Jacquemier, J., Penault-Llorca, F., et al. (2012) Ki-67: Level of Evidence and Methodological Considerations for Its Role in the Clinical Management of Breast Cancer: Analytical and Critical Review. Breast Cancer Research and Treatment, 132, 895-915.
http://dx.doi.org/10.1007/s10549-011-1837-z

[18]   Yerushalmi, R., Woods, R., Ravdin, P.M., Hayes, M.M. and Gelmon, K.A. (2010) Ki67 in Breast Cancer: Prognostic and Predictive Potential. The Lancet Oncology, 11, 174-183.
http://dx.doi.org/10.1016/S1470-2045(09)70262-1

[19]   Goldhirsch, A., Wood, W.C., Coates, A.S., Gelber, R.D., Thürlimann, B., Senn, H.J., et al. (2011) Strategies for Subtypes—Dealing with the Diversity of Breast Cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 22, 1736-1747.